Previous close | 19.79 |
Open | 19.62 |
Bid | 20.71 x 1100 |
Ask | 20.72 x 800 |
Day's range | 19.57 - 20.76 |
52-week range | 19.57 - 34.78 |
Volume | |
Avg. volume | 623,325 |
Market cap | 2.852B |
Beta (5Y monthly) | 1.26 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.03 |
Earnings date | 01 Nov 2023 - 06 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 55.60 |
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
There wouldn't be many who think Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 9.9x is...